# AGX-148

Source: https://onco.cc/drugs/agx-148/  
OnCo record `agx-148` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AGX-148 is an experimental cell therapy from AgonOx made from the tumour-recognising immune cells in a patient's own tumour. It is in an early trial in solid tumours.

## Summary

AGX-148 is AgonOx's lead TIL programme. AgonOx sponsors NCT05902520, a phase 1 trial of cancer-specific CD8 tumour-infiltrating lymphocytes in adults with solid tumours, listed on ClinicalTrials.gov as active and not recruiting, and a 2026 National Cancer Institute SBIR award funds its development for breast cancer.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: CD39+CD103+ double-positive TIL
- Tags: pipeline
- Code: AGX-148
- Modality: Autologous tumour-infiltrating lymphocyte therapy
- Mechanism: A patient's own CD8 tumour-infiltrating lymphocytes, enriched for the CD39-positive, CD103-positive subset that AgonOx describes as tumour-reactive, expanded and infused back.

## Sources

- AgonOx: https://www.agonox.com/
- ClinicalTrials.gov: NCT05902520: https://clinicaltrials.gov/study/NCT05902520

## Connected records

- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- companies: [AgonOx](https://onco.cc/companies/agonox/)

---
JSON: https://onco.cc/api/v1/entities/agx-148.json